Caspian Therapeutics outlines KO-7246 path to Phase 1 in diabetes
Caspian Therapeutics and its parent Kura Oncology have outlined the clinical development strategy for KO-7246, a selective oral menin inhibitor being positioned as a potential treatment for diabetes by targeting beta cell regeneration. The companies presented preclinical data at the 62nd European Association for the Study of Diabetes annual meeting in support of a planned Phase 1 proof-of-concept study assessing safety and endogenous insulin production.
Kura launched Caspian in September 2026, contributing KO-7246 and related intellectual property in exchange for approximately half ownership of the new company. A $50 million seed financing, led by BVF Partners with participation from T1D Fund, Invus, Montanova, Eli Lilly and Company, and Kura itself, will fund IND-enabling work and advancement of a second menin inhibitor candidate. Caspian operates with its own leadership team but draws on Kura's research and development capabilities through an intercompany services agreement.
Scientific rationale
The biological hypothesis behind KO-7246 draws on observations from pregnancy, during which reduced menin levels appear to release a constraint on beta cell proliferation, allowing the insulin-producing cell population to expand. Caspian is seeking to replicate that adaptive mechanism pharmacologically. In a mouse model of Type 2 diabetes, KO-7246 increased insulin levels and expanded beta cell mass; when combined with semaglutide, the compound produced a rapid reduction in blood glucose followed by a sustained effect, with no hypoglycaemia observed. In a rat model of severe insulin deficiency, responding animals regained normal glucose control, and elevated stimulated C-peptide levels persisted for one month after dosing stopped. Caspian also reported that KO-7246 selectively stimulated beta cell proliferation in human islet microtissue samples from multiple donors without increasing proliferation in other cell types, a finding the company says supports translation to human biology.
Rob Spencer, President and Chief Operating Officer of Caspian, said the Phase 1 programme will "characterize KO-7246's safety, tolerability and exposure and look for evidence of improved endogenous insulin production in people with either Type 1 or Type 2 diabetes." Stimulated C-peptide during treatment and follow-up will serve as the primary biological readout.
Market context
Menin inhibition is already a validated mechanism in oncology. Kura's own KOMZIFTI (ziftomenib) received FDA approval for relapsed or refractory NPM1-mutated acute myeloid leukaemia, giving the company a proprietary knowledge base in menin biology that Caspian is now attempting to redirect towards metabolic disease. The participation of Eli Lilly in the financing round is notable: Lilly is the world's largest insulin manufacturer and the developer of tirzepatide, and its interest in a beta-cell regeneration approach signals commercial validation at the highest tier of the diabetes market.
The broader competitive landscape for beta cell preservation and regeneration therapies remains early-stage. A number of academic groups and biotechs are pursuing GLP-1 combinations, islet transplantation, and stem-cell-derived beta cell programmes. KO-7246's differentiation claim rests on its oral bioavailability, its proposed regenerative rather than merely protective mechanism, and the durable post-treatment effects observed in animal models. Those claims will require rigorous human data to hold. The preclinical package is encouraging, but regulators and investors will rightly treat the translation gap between mouse beta cell biology and human outcomes as the central risk in this programme. IND clearance and early Phase 1 readouts on C-peptide are therefore the pivotal near-term milestones for Caspian.